|
|
|
|
|
Volume 40, Number 6, December 2007
| | In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections |
|---|
Tung-Yuan Tsai1, Shan-Chwen Chang2, Po-Ren Hsueh2,3, Nan-Hsiung Feng1, Jann-Tay Wang2
1Department of Internal Medicine, Kaohsiung Military General Hospital, Kaohsiung; and Departments of 2Internal Medicine and 3Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
Received: May 30, 2006 Revised: August 20, 2006 Accepted: August 23, 2006
Corresponding author: Dr. Jann-Tay Wang, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung-Shan South Road, Taipei 100, Taiwan. E-Mail:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Background and Purpose: Isepamicin is a newly introduced aminoglycoside in Taiwan. Since in vitro data for isepamicin against nosocomial Gram-negative bloodstream infection from Taiwan are limited, we compared the activity of isepamicin, amikacin, gentamicin and tobramycin against nosocomial Gram-negative blood isolates.
Methods: A total of 247 non-duplicate nosocomial blood isolates of Gram-negative bacteria collected between January 2003 and December 2003 in a major teaching hospital in Taiwan were tested for their in vitro susceptibilities to gentamicin, tobramycin, amikacin, and isepamicin using the agar dilution method. The isolates included Escherichia coli (31 isolates), Klebsiella pneumoniae (31), Enterobacter cloacae (30), Serratia marcescens (31), Morganella morganii (21), Citrobacter freundii (10), Pseudomonas aeruginosa (31), Acinetobacter baumannii (31), and Stenotrophomonas maltophilia (31).
Results: Overall, isepamicin had high antibacterial activity against the tested Gram-negative bacteria. For the 154 Enterobacteriaceae isolates, isepamicin had the lowest minimum concentration inhibiting 90% of isolates (MIC90) among the tested drugs, while its resistance rate (3.9%) was equal to that of amikacin (3.9%) and lower than those of tobramycin (18.2%) and gentamicin (21.4%). For the 93 of non-fermentative Gram-negative bacilli isolates, isepamicin had the lowest MIC90, and a resistance rate (23.7%) lower than those of amikacin (27.9%), tobramycin (38.7%) and gentamicin (40.9%).
Conclusions: The in vitro activity of isepamicin against Gram-negative bacteria isolates was equal or similar to amikacin and superior to other tested aminoglycosides. In view of its potential for less nephrotoxicity and ototoxicity than other aminoglycosides, isepamicin is a drug of choice for the empirical treatment of nosocomial infections caused by Gram-negative bacteria.
Key words: Aminoglycosides; Antimicrobial sensitivity tests; Drug resistance, bacterial; Gram-negative bacteria; Isepamicin
J Microbiol Immunol Infect. 2007;40:481-486.
| |
|
|
